# A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

> **NCT01564914** · PHASE2 · COMPLETED · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 22 (actual)

## Conditions studied

- Glioblastoma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** TRC105
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01564914
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2019-06-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01564914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01564914, "A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01564914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*